VYNE Therapeutics (NASDAQ:VYNE) Stock, Quote.Headers.trade-ideas

VYNE THERAPEUTICS INC

VYNE Therapeutics

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

Silver,Spring,,Md,,Usa,-,June,25,,2022:,The,Fda

Biotech

News

Health Care

Movers

Trading Ideas

General

VYNE

VYNE pauses VYN202 psoriasis trial after FDA clinical hold tied to animal toxicity data; separate vitiligo trial remains on track for mid-2025 results.

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

Movers_Stocks

ASAN

CRVO

CUTR

FWRG

GMHS

KUKE

LFMD

LZMH

NPWR

SNOA

SPRC

STSS

TNON

TSVT

Why Paymentus Holdings Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket

Long Ideas

Penny Stocks

Pre-Market Outlook

Markets

ALVR

ALPS ETF Trusthen & Steers Global Realty Majors ETF

IBIO

The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That May Rocket Higher In Q1

VYNE Therapeutics Inc

Press Releases

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

Earnings

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Analyst Ratings

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

VYNE Therapeutics to Participate in March Investor Conferences

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

VYNE Therapeutics Provides Update on VYN202 Program

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Hldgs

Athira Pharma

Aytu BioPharma

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Cingulate

Cocrystal Pharma

China Pharma Holding

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Durect

Gelteq

Hoth Therapeutics

Impact BioMedical

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lexaria Bioscience

Lipocine

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

ProPhase Labs

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Talphera

TherapeuticsMD

HC Wainwright & Co.

BTIG

Cantor Fitzgerald

Comments

VYNE Therapeutics

VYNE Therapeutics (NASDAQ:VYNE) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell